Staging of cancer

Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study

“…In addition, while older patients (especially those ≥70 years of age) are underrepresented in interventional clinical trials [16][17][18], 29% of patients observed in the FRAME study were ≥70 years of age. Certain baseline characteristics are known to be prognostic factors, such as PS and disease stage [19] and, as reported by the physicians in this study, PS, histopathological/cytological diagnosis as well as age are key factors in the choice of the FLT [12]. Since patients were not randomized to treatment cohorts in FRAME, baseline characteristics including age, gender, PS and stage, varied significantly (p < 0.01) among cohorts and outcomes should not be directly compared among cohorts.…”

“…The study included a total of 197 sites across 11 European countries; the majority of patients were in Germany (30%) and France (28%) [12]. Four FLT cohorts that included 1524 patients total (pemetrexed + platinum [n = 569, 37.3%], gemcitabine + platinum [n = 360, 23.6%], taxanes + platinum [n = 295, 19.4%], vinorelbine + platinum [n = 300, 19.7%]), were included in the outcomes analyses (CON-SORT Diagram [ Fig. 1]); 40 additional patients who received "other CONSORT diagram for the FRAME study.…”